secwatch.observer — SEC 8-K summary
======================================

Issuer:     RECURSION PHARMACEUTICALS, INC. (RXRX)
CIK:        0001601830
Form:       8-K
Filed at:   2025-05-05T23:59:59+00:00
Accession:  0001601830-25-000074
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Recursion Q1 net loss widens to $202.5M; Sanofi milestone $7M; pipeline refocused
--------------------------------------------------------------------------------

- Q1 net loss $202.5M vs $91.4M YoY; revenue $15M (up from $14M).
- Cash & equivalents $509M; projected cash runway into mid-2027; 2025 cash burn ≤$450M.
- Achieved 4th Sanofi milestone, $7M payment; total Sanofi cash inflow $130M to date.
- Deprioritized 3 clinical programs (REC-2282, REC-994, REC-3964) to focus on oncology and rare disease.
- REC-4881 preliminary data: median 43% polyp burden reduction in FAP Phase 1b/2 study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601830/000160183025000074/0001601830-25-000074-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601830/000160183025000074/rxrx-20250505.htm
  HTML page:      https://secwatch.observer/filing/0001601830-25-000074

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer